Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 131


Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

Taylor BS, Hunt G, Abrams EJ, Coovadia A, Meyers T, Sherman G, Strehlau R, Morris L, Kuhn L.

AIDS Res Hum Retroviruses. 2011 Sep;27(9):945-56. doi: 10.1089/AID.2010.0205. Epub 2011 Mar 23.


It is time to consider third-line options in antiretroviral-experienced paediatric patients?

Zyl GU, Rabie H, Nuttall JJ, Cotton MF.

J Int AIDS Soc. 2011 Nov 15;14:55. doi: 10.1186/1758-2652-14-55.


Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2012 Apr;67(4):995-1000. doi: 10.1093/jac/dkr569. Epub 2012 Jan 17.


Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;5:CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.


Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.

Frange P, Briand N, Avettand-fenoel V, Veber F, Moshous D, Mahlaoui N, Rouzioux C, Blanche S, Chaix ML.

Pediatr Infect Dis J. 2011 Aug;30(8):684-8. doi: 10.1097/INF.0b013e31821752d6.


Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.

Meyers T, Sawry S, Wong JY, Moultrie H, Pinillos F, Fairlie L, van Zyl G.

Pediatr Infect Dis J. 2015 Feb;34(2):175-9. doi: 10.1097/INF.0000000000000544.


Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.


First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.

Clumeck N, Mwamba C, Kabeya K, Matanda S, Vaira D, Necsoi C, Kadiebwe D, Delforge M, Kasamba E, Milolo C, Ilunga J, Kapend L.

AIDS. 2014 May 15;28(8):1143-53. doi: 10.1097/QAD.0000000000000214.


Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.

Moorthy A, Kuhn L, Coovadia A, Meyers T, Strehlau R, Sherman G, Tsai WY, Chen YH, Abrams EJ, Persaud D.

Clin Infect Dis. 2011 Feb 15;52(4):514-21. doi: 10.1093/cid/ciq161. Epub 2011 Jan 22.


Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.

Reitz C, Coovadia A, Ko S, Meyers T, Strehlau R, Sherman G, Kuhn L, Abrams EJ.

J Infect Dis. 2010 Apr 15;201(8):1121-31. doi: 10.1086/651454.


Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy.

Lange CM, Hué S, Violari A, Cotton M, Gibb D, Babiker A, Otwombe K, Panchia R, Dobbels E, Jean-Philippe P, McIntyre JA, Pillay D, Gupta RK.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):138-44. doi: 10.1097/QAI.0000000000000568.


Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.

Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, Sherman G, Hunt G, Persaud D, Morris L, Tsai WY, Abrams EJ.

Lancet Infect Dis. 2012 Jul;12(7):521-30. doi: 10.1016/S1473-3099(12)70051-8. Epub 2012 Mar 16.


HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.

Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L.

AIDS Res Hum Retroviruses. 2008 Nov;24(11):1449-54. doi: 10.1089/aid.2008.0180.


Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.

Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L.

Clin Infect Dis. 2009 Feb 15;48(4):462-72. doi: 10.1086/596486.


Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V.

Pediatr Infect Dis J. 2009 Sep;28(9):826-30. doi: 10.1097/INF.0b013e3181a458f9.


HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, Kuhn L.

AIDS. 2011 Jul 31;25(12):1461-9. doi: 10.1097/QAD.0b013e3283492180.


Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?

Champenois K, Baras A, Choisy P, Ajana F, Melliez H, Bocket L, Yazdanpanah Y.

J Med Virol. 2011 Oct;83(10):1677-81. doi: 10.1002/jmv.22161. Epub 2011 Jul 13.


Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group.

J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927.


Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.

Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L.

JAMA. 2010 Sep 8;304(10):1082-90. doi: 10.1001/jama.2010.1278.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk